Free Trial

DiaMedica Therapeutics Q2 2024 Earnings Report

DiaMedica Therapeutics logo
$5.38 -1.03 (-16.07%)
(As of 05:26 PM ET)

DiaMedica Therapeutics EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.16
Beat/Miss
Beat by +$0.03
One Year Ago EPS
-$0.16

DiaMedica Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

DiaMedica Therapeutics Announcement Details

Quarter
Q2 2024
Time
After Market Closes

Conference Call Resources

Conference Call Audio

Your chance to get on the next “60-Second Trade” (Ad)

Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!

Just head over here!

DiaMedica Therapeutics Earnings Headlines

70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!
Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.
DiaMedica Therapeutics doses first patient in Phase 2 DM199 trial
See More DiaMedica Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like DiaMedica Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DiaMedica Therapeutics and other key companies, straight to your email.

About DiaMedica Therapeutics

DiaMedica Therapeutics (NASDAQ:DMAC), a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

View DiaMedica Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings